Aller au contenu principal
Accès ouvert déclaré 2026 article

P-709. Incidence of Hospitalizations for Laboratory-Confirmed RSV, COVID-19, and Influenza among Children under-18 years — Respiratory Virus Hospitalization Surveillance Network (RESP-NET), United States, 2022–2024

0Citations signalées — pas une note de qualité
13Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Background Respiratory syncytial virus (RSV), SARS-CoV-2, and influenza virus infections are leading causes of severe illness in children. We compared population-based pediatric hospitalization rates for illness associated with these viruses using the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). Methods Children < 18 years hospitalized with RSV, COVID-19, and influenza during October 2022–September 2024 were identified in RESP-NET, which includes patients with positive screening or clinician-directed laboratory test for each virus ≤14 days prior to or during hospitalization at >300 U.S. hospitals. We calculated hospitalization rates by age group and surveillance period, and incidence rate ratios. Results During 2022–2024, 15,843/17,353 (91%) hospitalizations with RSV, 4137/6041 (68%) with COVID-19, and 2822/5863 (48%) with influenza occurred in < 5 year-olds (Table); this age group had the highest hospitalization rates (Figure). Among 0–5 month-olds, RSV hospitalization rates during 2022–2023 and 2023–2024 were 18.0 (15.3–21.5) and 12.4 (10.5–14.9) times higher than respective influenza rates; COVID-19 rates were 4.3 (3.4–5.1) and 3.4 (2.8–4.2) times higher. Among 6–59 month-olds, RSV hospitalization rates were 5.4 (5.0–5.9) and 4.3 (3.9–4.7) times higher; COVID-19 rates did not differ statistically from influenza rates. Among 5–11 year-olds, RSV hospitalization rates were 0.5 (0.4–0.6) times influenza rates in 2023–2024, but not statistically different in 2022–2023; COVID-19 hospitalization rates were 0.4 (0.4–0.5) and 0.3 (0.2–0.3) times influenza rates in 2022–2023 and 2023–2024 respectively. Among 12–17 year-olds, RSV hospitalization rates were 0.3 (0.2–0.4) and 0.3 (0.3–0.4) times influenza rates during 2022-2023 and 2022–2024; COVID-19 rates were 1.3 (1.1–1.5) times influenza rates in 2022-2023 but not statistically different in 2022–2024. Conclusion RSV accounted for the highest hospitalization rates among infants and young children. Among children 5–17 years, hospitalization rates were lower than among those < 5 years and differences in rates between viruses were less pronounced. These findings can help identify age groups at highest risk of hospitalization for each virus and can help guide prevention and treatment strategies. Disclosures Melissa Sutton, MD, MPH, Centers for Disease Control and Prevention Emerging Infections Program: Grant/Research Support

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
P-709. Incidence of Hospitalizations for Laboratory-Confirmed RSV, COVID-19, and Influenza among Children under-18 years — Respiratory Virus Hospitalization Surveillance Network (RESP-NET), United States, 2022–2024
Date Crossref
01/01/2026
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Respiratory viral infections researchCOVID-19 Clinical Research StudiesPneumonia and Respiratory Infections

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.